Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899166 | 1.00 | ABL1 (0.45) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL17126117 | 0.86 | NUDT1 (0.48) | NUDT1ALPLALDH1A1MAPT | |
| SCHEMBL31420506 | 0.86 | NUDT1 (0.41) | NUDT1DAOAXLPRKCI | |
| SCHEMBL26620152 | 0.83 | ABL1 (0.43) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL30883103 | 0.83 | ABL1 (0.43) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL23147720 | 0.83 | NUDT1 (0.46) | ABL1NUDT1SYKDAOAXL | |
| SCHEMBL20839678 | 0.83 | GRIN1 (0.46) | NUDT1DAOAXLPRKCI | |
| SCHEMBL30239581 | 0.83 | GRIN1 (0.46) | NUDT1DAOAXLPRKCI | |
| SCHEMBL22554309 | 0.82 | ABL1 (0.44) | ABL1SRCNUDT1CYP1A2DAO | |
| SCHEMBL20839976 | 0.82 | NUDT1 (0.63) | NUDT1SYKDAOMAPTAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4405343-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-07-31 | — | — | EP | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4182323-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023046698-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |